Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
Amgen halts trials on cardiac toxicity | Evaluate
Amgen shares hit after analysts expose buried FDA trial halt | Fierce Biotech
AMG-176 | Cas# 1883727-34-1 - GlpBio
AMG 176 | New Drug Approvals
Kyprolis-Plus-Darzalex Boosts Amgen's Myeloma Pipeline, After MCL-1 Drugs' Clinical Holds :: Scrip
tapotoclax (AMG 176) / Amgen, Roche, AbbVie, BeiGene
AMG176 - Multiple Myeloma Clinical Trials
Updates and rationale of clinical trials in multiple myeloma - Branagan - 2019 - ADVANCES IN CELL AND GENE THERAPY - Wiley Online Library
AstraZeneca Cancer Trial Hit with Clinical Hold Following Cardiac Issues | BioSpace
Clinical Trials and New Therapies for Multiple Myeloma | The MMRF
AMG-176 | Cas# 1883727-34-1 - GlpBio
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
AMG 176 | New Drug Approvals
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapi
Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
AMG 176 | New Drug Approvals
StudyPages - First in-Human Trial of the Experimental Drug AMG 176 in Relapsed or Refractory (re-occurring) Cancer of the Blood Systems
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
AMG 176 Myeloma Trials
Cancers | Free Full-Text | Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.
AMGEN at SITC
